KRAS and colorectal cancer: Reports from Taiwan of KRAS wild-type colorectal cancer refractory to two or three regimens [64] and from Italy of RAS/BRAF wild-type colorectal cancer refractory to two or three regimens [65] both suggested that the therapeutic effect of anti-EGFR antibodies is better in left-sided colorectal cancer.